Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
250
datasets available to search
ShareScore release 0.9.0
Dataset results
250 results for “Clinical biomarker”
Dataset of clinical biomarkers for prediction of the arboviral infection severity using SIMON analysis
<p>The SISA dataset was used for the identification of clinical biomarkers that can predict the severity of the arboviral infection severity using SIMON analysis, as described (<a href="https://doi.org/10.1101/2020.08.16.252767">https://doi.org/10.1101/2020.08.16.252767</a>). The dataset contains clinical data from 543 individuals hospitalized due to the arboviral infection with Dengue, chikungunya, or Zika viruses from a surveillance study in Ecuador collected from 2013 to 2017 (Suppy et al., 2020, doi: 10.1371/journal.pntd.0007969). In the SISA dataset, we have excluded columns with high level of missing values (pregnancy, <em>WomPreg</em> and complete blood count test which was not performed for all donors and includes columns: <em>PLT_count, Lymphocytes, CBC_N%, WBC_calc </em>and<em> CBC_HCT</em>). Additionally, 9 donors with missing values were removed and SIMON analysis was performed with this final dataset.</p>
Dateset related to article "Cytokines as potential biomarkers of disease clinical course in muscular dystrophies "
<p>This database includes a comprehensive profile of circulating pro- and anti-inflammatory molecules (cytokines, chemokines and growth factors) obtained from a group of 53 patients with muscular laminopathy, 10 with non-muscular laminopathy, 22 with other muscular disorders and 35 healthy controls. Data obtained by Luminex multiple immune-assay identify TGF-b2, IL-17 and G-CSF as potential biomarkers in discriminating between muscle-related laminopathy and healthy subjects. The different expression of IL-1b, IL-4 and IL-8 among the different forms of laminopathy provides a new hint for the understanding of the pathogenic mechanisms underlying the diverse phenotypes caused by <em>LMNA</em> mutations.</p>
A more accurate risk biomarkers recognition for Progressive Multifocal Leukoencephalopathy (PML) caused by Polyomavirus JC in patients with multiple sclerosis during treatment with disease-modifying therapies (DMTs): an ongoing clinical challenge.
<p>The therapeutic scenario for the treatment of MS has recently been characterized by a veritable revolution, which has included the introduction, for the first time, of drug treatment guidelines and the entry, in the therapeutic landscape of the last decade, of numerous new drugs that, in varying but significantly relevant ways, have proven capable of modifying the course of the disease (Disease-Modifying Therapies - DMTs). <br> While the arsenal of available drugs has resulted in advances in efficacy and selectivity, it has also exposed them to the danger of side effects, potentially serious and in some cases even fatal. Among the most important side effects, complications of infectious origin, characterized by cases of viral infection/reactivation, as in the case of JCPyV, the etiologic agent of PML, are the most represented. This study, based on the follow-up of MS patients treated with different DMTs, contributes to implementing the data in the literature regarding a greater understanding of the risks related to the administration of these drugs and more appropriate monitoring of MS treatment. The risk of JCPyV reactivation with Fingolimod and Dimethyl fumarate is lower than the risk of viral reactivation associated with natalizumab.<br> In light of the data obtained, it is possible to conclude that, in the case of natalizumab, testing for JC viruria would seem to be more useful in identifying those patients with a JCPyV-specific humoral response that is not yet detectable. In addition, our results, draw attention to the importance of analyzing the NCCR rearrangements of JCPyV. Indeed, the particular rearrangements found in plasma and PBMCs of patients with RRMS treated with natalizumab could represent an alert of neuroinvasiveness in order to detect early those patients with a higher risk of developing PML. In the case of dimethyl fumarate, it seems likely that monitoring of lymphopenia would identify a higher risk group of patients in whom alternative therapy should be sought. Prolonged lymphopenia, with absolute lymphocyte counts less than 750 lymphocytes/mL, might be the major risk factor for PML although, a greater risk might lie in the loss of CD8+ cells that are crucial for JCPyV control.<br> For fingolimod, this strategy cannot be applied because the number of circulating lymphocytes decreases while the actual lymphocyte function appears largely normal therefore, monitoring viruria and viremia along with identification of the neurotrophic variant of the virus seems a more exploitable means for risk stratification.</p> <p>In conclusion, the results of this study can be considered directly transferable to the National Health System in that, both the monitoring of JCPyV reactivation by viruria and the sequence analysis of viral NCCR and host immune set-up could play the role of translatable biomarkers in clinical practice in order to assess the risk of PML onset. In addition to improving risk stratification of this disease, these biomarkers of viral reactivation and pathogenicity could facilitate timely diagnosis, optimizing the use of health care resources and contributing to the reduction of direct and indirect costs of MS disease.</p> <p>Prezioso Carla was supported by the Italian Ministry of Health (Starting Grant: SG-2018-12366194).</p>
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
ClinicalTrials.gov study NCT04567628. IPD Sharing: YES. Countries: 1. Publications: 1.
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies
ClinicalTrials.gov study NCT03888222. IPD Sharing: NO. Countries: 1. Publications: 1.
Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer
ClinicalTrials.gov study NCT01762813. IPD Sharing: UNDECIDED. Countries: 1. Publications: 6.
Effectiveness of Immersive Virtual Reality on Biomarkers and Clinical and Clinimetric Variables in Patients with Persistent Shoulder Pain
ClinicalTrials.gov study NCT06795464. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Comparing Biomarker-Guided DBS Programming With Standard Clinical Monopolar Programming
ClinicalTrials.gov study NCT07369310. IPD Sharing: NO. Countries: 1. Publications: 3.
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients
ClinicalTrials.gov study NCT05911711. IPD Sharing: YES. Countries: 1. Publications: 2.
NSAID Effects on Clinical and Imaging Breast Biomarkers
ClinicalTrials.gov study NCT01761877. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Implementing a Combination of Clinical Parameters, Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients
ClinicalTrials.gov study NCT03366454. IPD Sharing: NO. Countries: 1. Publications: 1.
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
ClinicalTrials.gov study NCT03156504. IPD Sharing: NO. Countries: 1. Publications: 2.
The Clinical Significance of CT-based Biomarkers in the Classification and Prognosis of Bronchiectasis
ClinicalTrials.gov study NCT06346938. IPD Sharing: YES. Countries: 1. Publications: 16.
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
ClinicalTrials.gov study NCT04004000. IPD Sharing: NO. Countries: 1. Publications: 5.
Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM
ClinicalTrials.gov study NCT02850432. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Data from: Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma
The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liver Cancer (BCLC) staging system and prognosis of patients with hepatocellular carcinoma (HCC). We downloaded 4 gene expression datasets from the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo), and screened for genes that were differentially expressed between HCC and normal liver tissues, using significance analysis of the microarray algorithm. We used a weighted gene co-expression network analysis (WGCNA) to identify hub genes that correlate with BCLC staging, functional enrichment analysis to associate hub genes with their functions, protein-protein interaction network analysis to identify interactions among hub genes, UALCAN analysis to assess gene expression levels based on tumour stage, and survival analyses to clarify the effects of hub genes on patients' overall survival (OS). We identified 50 relevant hub genes using WGCNA; among them, 13 genes (including TIGD5, C8ORF33, NUDCD1, INSB8, and STIP1) correlated with OS and BCLC staging. Significantly enriched gene ontology biological process terms included RNA processing, non-coding RNA processing and phosphodiester bond hydrolysis, and 6 genes were found to interact with 10 or more hub genes. We identified several candidate biomarkers that correlate with BCLC staging and OS of HCC. These genes might be used for prognostic assessment and selection of HCC patients for surgery, especially those with intermediate or advanced disease.
Digital BIOmarkers for the Assessment of Motor Status in Parkinson's Disease Patients with CLInical and ThErapeutic Application
ClinicalTrials.gov study NCT06817772. IPD Sharing: NO. Countries: 1. Publications: 2.
An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Osteoarthritis of the Knee
ClinicalTrials.gov study NCT03100799. IPD Sharing: NO. Countries: 1. Publications: 4.
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
ClinicalTrials.gov study NCT05137665. IPD Sharing: YES. Countries: 3. Publications: 9.
Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology
ClinicalTrials.gov study NCT04389541. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.